2009
Th17 Cells Are Not Required for Host Defense Against Murine Disseminated Candidiasis, But Are Required for Vaccine-Mediated Protection (132.10)
Lin L, Ibrahim A, Avanesian V, Xu X, Farber J, Fu Y, Baquir B, Spellberg B. Th17 Cells Are Not Required for Host Defense Against Murine Disseminated Candidiasis, But Are Required for Vaccine-Mediated Protection (132.10). The Journal Of Immunology 2009, 182: 132.10-132.10. DOI: 10.4049/jimmunol.182.supp.132.10.Peer-Reviewed Original ResearchCCR6-deficient miceDisseminated candidiasisVaccine-mediated protectionTh17 cellsIL-17Control miceRAls3p-NVaccine efficacyDeficient miceSusceptible to disseminated candidiasisCD4+IL-17+Wild type control miceMurine disseminated candidiasisRecombinant N-terminusLevels of IFNCompare Th1Th1/17 cellsT lymphocytesUnvaccinated miceC. albicansCandidiasisVaccinated miceTail veinTh17Candidal adhesin
1995
Efficacy of Human Lyme Disease Vaccine Formulations in a Mouse Model
Telford SR, Kantor FS, Lobet Y, Barthold SW, Spielman A, Flavell RA, Fikrig E. Efficacy of Human Lyme Disease Vaccine Formulations in a Mouse Model. The Journal Of Infectious Diseases 1995, 171: 1368-1370. PMID: 7751719, DOI: 10.1093/infdis/171.5.1368.Peer-Reviewed Original ResearchConceptsMouse modelC3H/HeJ mouse modelLyme diseaseRecombinant outer surface protein APhase I human trialsPhase II trialSurface protein AUnvaccinated miceII trialVaccinated miceOuter surface protein AVaccine formulationsHuman trialsRecombinant OspAMiceBorrelia burgdorferiDiseaseTrialsMajor siteTrial sitesProtein ATicksImmunizationVaccineInfection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply